Korean J Obstet Gynecol Search

CLOSE


Obstet Gynecol Sci > Volume 54(3); 2011 > Article
Korean Journal of Obstetrics & Gynecology 2011;54(3):127-131.
DOI: https://doi.org/10.5468/KJOG.2011.54.3.127    Published online March 1, 2011.
Prophylactic antiemetics therapy against gynecologic cancer chemotherapy.
Keun Ho Lee, Yong Il Kwon
1Department of Obstetrics & Gynecology, The Catholic University of Korea School of Medicine, Seoul, Korea.
2Department of Obstetrics & Gynecology, Hallym University School of Medicine, Seoul, Korea. kbgy@hallym.or.kr
Abstract
Nausea and vomiting associated with gynecologic cancer chemotherapy are experienced by most of patients receiving chemotherapy. Assessment of vomiting risk by chemotherapy and risk factor are mandatory for rescue of chemotherapy induced nausea and vomiting (CINV). Piled-up evidence based medicine result in prophylactic antiemetics guideline from American Society of Clinical Oncology, Multinational Association for Supportive Care in Cancer, and National Comprehensive Cancer Network. Combination of serotonin receptor antagonist, dexamethason, and with/without NK1 antagonist is the best prophylaxis in patients receiving highly and moderate emetogenic chemotherapy. Other new regimens (palonosetron, transdermal granisetron) are introduced to relieve the active symptom of delayed CINV. Comprehensive understading of pathophysiology of CINV and tailored therapy for the patients are vital in prophylactic antiemetics therapy against gynecologic cancer chemotherapy.
Key Words: Nausea, Vomiting, Antiemetics, Guideline


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
POLICY
FOR CONTRIBUTORS
Editorial Office
4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea
Tel: +82-2-3445-2382    Fax: +82-2-3445-2440    E-mail: journal@ogscience.org                

Copyright © 2022 by Korean Society of Obstetrics and Gynecology.

Developed in M2PI

Close layer
prev next